ResMed (ASX:RMD) share price on watch after Q2 update disappoints

ResMed shares will be in focus today after its Q2 results fell short of expectations.

| More on:
A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResMed delivered solid revenue and profit growth in the second quarter
  • A major competitor product recall boosted demand
  • However, its revenue still fell short of analyst expectations

The ResMed Inc. (ASX: RMD) share price will be one to watch on Friday morning.

This follows the release of the sleep treatment focused medical device company's second quarter update.

ResMed share price on watch after falling short of expectations

  • Revenue increased 12% (13% in constant currency) to US$894.9 million
  • Gross margin contracted by 230 basis points to 57.6%
  • Net income up 12% to US$201.8 million
  • Diluted earnings per share up 11% to US$1.37
  • Quarterly dividend of 42 US cents declared

What happened during the quarter?

For the three months ended 31 December, ResMed reported a 12% increase in revenue to US$894.9 million. This was driven by increased demand for sleep and respiratory care devices and the benefits of a major product recall by one of its largest competitors.

ResMed recorded top line growth across all its operations. Revenue in the Americas grew 14%, in Europe, Asia, and other markets it grew 12%, and its software-as-a-service business reported 8% revenue growth.

However, while this revenue growth was strong, it still fell short of the market's expectations. The consensus estimate was for revenue of US$927.5 million. In after hours trade in the US, the ResMed share price is down 4.5% on the news.

Also potentially weighing on the ResMed share price today was its softer gross margin. Management advised that its gross margin decreased by 230 basis points due to higher freight and manufacturing costs, which were partially offset by favourable product mix changes.

Management commentary

ResMed's CEO, Mick Farrell, was pleased with the company's performance during the quarter, especially given the supply chain challenges it was facing.

He said: "Our second-quarter results reflect continued strong performance across our business resulting in double-digit top-line revenue growth, driven by ongoing high demand for our sleep and respiratory care products, and solid growth in our software-as-a-service business. Our global ResMed team continues to find ways to deliver products and solutions to our customers, even amid ongoing supply chain challenges that have limited additional access to critical electronic components."

"We are working every day to meet the extraordinary demand generated by our competitor's ongoing device recall. We continue to ensure priority for the highest-need patients first, and we are working with physicians, providers, and healthcare systems to maintain delivery of medical devices and digital health solutions for the patients who need care," he added.

Mr Farrell remains positive on the future and notes that the company continues to focus on improving 250 million lives by 2025.

He commented: "Despite constantly evolving market dynamics, we remain focused on our goal to improve 250 million lives in the year 2025; supporting patients with the sleep apnea therapy, respiratory care therapy, and digital health solutions they need as we deliver value for all of our customers."

"We are investing in medical device research and development, as well as digital health innovation that will unlock value across the healthcare system. I am incredibly proud of our global ResMed team, working around the clock with providers and physicians across 140 countries to get products directly into the hands of patients who most need our help," Mr Farrell concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

Business people discussing project on digital tablet.
Earnings Results

2 ASX All Ords shares surging over 10% on strong results

Investors are buying these shares in response to strong results this morning.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Earnings Results

Xero share price rockets to record high on explosive half-year growth

The tech star delivered another impressive half year results this morning.

Read more »

A man cheers after winning computer game while woman sitting next to him looks upset.
Earnings Results

2 high-flying ASX 200 gaming shares splitting ways today

Which gaming giant is winning the admiration of investors amid results?

Read more »

Male building supervisor wearing high vis vest and hard hat stands and smiles with his arms crossed at a building site
Industrials Shares

This $23 billion ASX 200 stock is surging 6% while the market sinks. Here's why

This ASX 200 stock is shrugging off the wider market sell down today and racing higher. But why?

Read more »

Unsure man analysing data on laptop.
Earnings Results

ASX 200 tech stock sees red as investors punish Q3 results

Investors continue digesting the numbers.

Read more »

Female miner smiling in front of mining vehicle.
Resources Shares

Guess which ASX lithium share is racing 8% higher on record production

Investors are sending the ASX lithium share racing higher on Wednesday.

Read more »

A woman wearing yellow smiles and drinks coffee while on laptop.
Earnings Results

CBA shares on watch after delivering $2.5b quarterly profit

The banking giant has made a big quarterly profit. But will it be enough for the market?

Read more »

a farmer kneels on one leg and closely examines soil from his farm against a blue sky backdrop.
Earnings Results

ASX 200 consumer stock surges despite loss and dividend cut

Investors were quick to overlook the negatives.

Read more »